PEPTIDE

Exenatide (Byetta/Bydureon)

GLP-1 receptor agonist derived from Gila monster venom exendin-4; resistant to DPP-4. BID (Byetta) and weekly extended-release (Bydureon) formulations.

BIOGATE · GREEN | POSTERIOR 41.1% | MW 4186.6 | 39AA

SEQUENCE

HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Modifications: amidated C-terminus; 39-residue Heloderma exendin-4

PDA-V1 chain of custody

Outer hash

4-ee124e74de1235450e1280d4fe1267a4ae11e9b49e11d084ce121c1

Merkle root

51632344526324-d75363266a546327fd4d631cf84e631e8b4f63201e506321b1

Inputs

d735c667d635c4d4d935c98dd835c7fad335c01bd235be88d535c34

TEE attestation

28-f6917e29f6931126f68e5827f68feb2cf697ca2df6995d2af694a42bf69637

Living Outcome Oracle

± =52.7 ² =75.5 **P(success) = 41.1%** 95% CI [29.1%, 53.1%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A 2004 · Diabetes Care

Effects of exenatide (synthetic exendin-4) in type 2 diabetic patients on sulfonylureas

Buse JB et al.

PMID 16505503